New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Scribe Therapeutics Inc. (SCTX) SEC filings, changes and red flags

Red flags

No red flags have been raised by Scribe Therapeutics Inc.’s filings on file.

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026
8-K Nov 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Sep 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 27, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.